18. Lipoprotein-Based Nanoplatforms for Cancer Molecular Imaging

  1. Xiaoyuan Chen5,6
  1. Ian R. Corbin1,2,
  2. Kenneth Ng3 and
  3. Gang Zheng2,4

Published Online: 25 MAY 2011

DOI: 10.1002/9780470767047.ch18

Nanoplatform-Based Molecular Imaging

Nanoplatform-Based Molecular Imaging

How to Cite

Corbin, I. R., Ng, K. and Zheng, G. (2011) Lipoprotein-Based Nanoplatforms for Cancer Molecular Imaging, in Nanoplatform-Based Molecular Imaging (ed X. Chen), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470767047.ch18

Editor Information

  1. 5

    Molecular Imaging Program at Stanford and Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford, California, USA

  2. 6

    Laboratory for Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, USA

Author Information

  1. 1

    Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

  2. 2

    Division of Biophysics and Bioimaging, Ontario Cancer Institute, Toronto, Ontario, Canada

  3. 3

    Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

  4. 4

    Department of Medical Biophysics and Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada

Publication History

  1. Published Online: 25 MAY 2011
  2. Published Print: 28 MAR 2011

ISBN Information

Print ISBN: 9780470521151

Online ISBN: 9780470767047

SEARCH

Keywords:

  • nanoparticle platforms, as multimodality imaging and therapy agents - lipoprotein-based nanoplatforms in cancer molecular imaging;
  • lipoprotein (LDL and HDL) for cancer imaging - three main strategies, incorporating probes into lipoproteins;
  • HDL for tumor targeting - interest, in associating HDL with cancer

Summary

This chapter contains sections titled:

  • Lipoproteins: Nature's Endogenous Nanocarrier

  • Cancer Imaging with Lipoprotein Vehicles

  • HDL for Tumor Targeting

  • Rerouting Lipoproteins to Cancer Specific Targets

  • Future Direction for Lipoprotein-Based Carriers

  • Conclusion

  • Acknowledgment

  • References